John Reneau

694 total citations
34 papers, 385 citations indexed

About

John Reneau is a scholar working on Pathology and Forensic Medicine, Oncology and Immunology. According to data from OpenAlex, John Reneau has authored 34 papers receiving a total of 385 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Pathology and Forensic Medicine, 20 papers in Oncology and 13 papers in Immunology. Recurrent topics in John Reneau's work include Lymphoma Diagnosis and Treatment (21 papers), CAR-T cell therapy research (10 papers) and Cutaneous lymphoproliferative disorders research (9 papers). John Reneau is often cited by papers focused on Lymphoma Diagnosis and Treatment (21 papers), CAR-T cell therapy research (10 papers) and Cutaneous lymphoproliferative disorders research (9 papers). John Reneau collaborates with scholars based in United States, South Korea and Australia. John Reneau's co-authors include Ryang Hwa Lee, Darwin J. Prockop, Nara Yoon, Nikolay Bazhanov, Ji Min Yu, Joo Youn Oh, Andrea M. Foskett, Ryan A. Wilcox, Catherine Chung and Walter Hanel and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Blood and Cancer Research.

In The Last Decade

John Reneau

30 papers receiving 380 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
John Reneau United States 7 207 117 107 78 70 34 385
Valerie Eaton United States 7 318 1.5× 151 1.3× 66 0.6× 90 1.2× 134 1.9× 8 534
Yukina Morimoto Japan 14 196 0.9× 125 1.1× 126 1.2× 47 0.6× 114 1.6× 33 483
Wen Bai China 6 256 1.2× 108 0.9× 60 0.6× 63 0.8× 63 0.9× 7 381
Nakia D. Spencer United States 10 166 0.8× 116 1.0× 75 0.7× 136 1.7× 125 1.8× 14 439
Xinran Yuan China 6 219 1.1× 175 1.5× 60 0.6× 72 0.9× 148 2.1× 10 457
Kevin Anton United States 8 129 0.6× 106 0.9× 78 0.7× 60 0.8× 56 0.8× 17 405
Mihai Bogdan Preda Romania 11 227 1.1× 207 1.8× 59 0.6× 159 2.0× 85 1.2× 29 515
Simon Schliffke Germany 11 132 0.6× 254 2.2× 159 1.5× 97 1.2× 156 2.2× 15 549
Rosalba Camicia Switzerland 5 182 0.9× 226 1.9× 171 1.6× 91 1.2× 105 1.5× 5 490
Cristiana Lavazza Italy 15 192 0.9× 300 2.6× 97 0.9× 103 1.3× 92 1.3× 33 573

Countries citing papers authored by John Reneau

Since Specialization
Citations

This map shows the geographic impact of John Reneau's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Reneau with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Reneau more than expected).

Fields of papers citing papers by John Reneau

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Reneau. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Reneau. The network helps show where John Reneau may publish in the future.

Co-authorship network of co-authors of John Reneau

This figure shows the co-authorship network connecting the top 25 collaborators of John Reneau. A scholar is included among the top collaborators of John Reneau based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Reneau. John Reneau is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Brammer, Jonathan E., Zachary Braunstein, Patrick Stevens, et al.. (2025). Targeting the methylome in T-LGL leukemia: Pre-clinical analysis and Results of a Phase I trial with oral 5-azacytidine. Blood. 146(Supplement 1). 890–890.
2.
Reneau, John, et al.. (2024). Final Results of a Phase II Study of Brentuximab Vedotin and Lenalidomide in Relapsed and Refractory T-Cell Lymphomas. Blood. 144(Supplement 1). 4438–4438. 1 indexed citations
3.
Wang, Chenguang, Ying Hu, Ashley Wolfe, et al.. (2024). GATA-3–dependent Gene Transcription is Impaired upon HDAC Inhibition. Clinical Cancer Research. 30(5). 1054–1066. 4 indexed citations
4.
Huang, Ying, et al.. (2024). Observation of lymphadenopathy, systemic symptoms, and treatment in suspected indolent cutaneous B-cell lymphomas. Archives of Dermatological Research. 316(5). 199–199. 1 indexed citations
5.
Rosenbaum, James T., Erik Verner, William B. Jones, et al.. (2024). Synthesis and characterization of soquelitinib a selective ITK inhibitor that modulates tumor immunity. 1(1). 3 indexed citations
6.
7.
Braunstein, Zachary, Eric McLaughlin, Walter Hanel, et al.. (2023). Gemcitabine and liposomal doxorubicin (GemDox) for the treatment of relapsed and refractory T-cell lymphomas. Leukemia & lymphoma. 65(3). 301–311. 1 indexed citations
8.
Faisal, Muhammad Salman, Walter Hanel, Timothy Voorhees, et al.. (2023). Outcomes associated with allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma in the era of novel agents. Cancer Medicine. 12(7). 8228–8237. 2 indexed citations
9.
Reneau, John, et al.. (2023). Advancements in the treatment of mycosis fungoides and Sézary syndrome: monoclonal antibodies, immunotherapies, and Janus kinase inhibitors. Frontiers in Immunology. 14. 1291259–1291259. 4 indexed citations
10.
Weiss, J., John Reneau, & Ryan A. Wilcox. (2023). PTCL, NOS: An update on classification, risk-stratification, and treatment. Frontiers in Oncology. 13. 1101441–1101441. 10 indexed citations
11.
Murga‐Zamalloa, Carlos, John Reneau, Mirna L.M. Rodriguez, et al.. (2023). Successful anti-tumor effects with two novel bifunctional chemotherapeutic compounds that combine a LAT1 substrate with cytotoxic moieties in aggressive T-cell lymphomas. Leukemia Research Reports. 21. 100398–100398. 2 indexed citations
12.
Gao, Xin, Chenguang Wang, Peter H. Gann, et al.. (2022). Targeting Lymphoma-associated Macrophage Expansion via CSF1R/JAK Inhibition is a Therapeutic Vulnerability in Peripheral T-cell Lymphomas. Cancer Research Communications. 2(12). 1727–1737. 5 indexed citations
13.
Gao, Xin, Chenguang Wang, Carlos Murga‐Zamalloa, et al.. (2022). Notch Signaling Promotes Mature T-Cell Lymphomagenesis. Cancer Research. 82(20). 3763–3773. 6 indexed citations
14.
Bharti, Vijaya, Amrendra Kumar, Rebecca L. Shattuck-Brandt, et al.. (2022). BCL-xL inhibition potentiates cancer therapies by redirecting the outcome of p53 activation from senescence to apoptosis. Cell Reports. 41(12). 111826–111826. 29 indexed citations
15.
Kim, Eunsoo, Hannah Yu, Alice Baek, et al.. (2022). Comparison of CD3e Antibody and CD3e-sZAP Immunotoxin Treatment in Mice Identifies sZAP as the Main Driver of Vascular Leakage. Biomedicines. 10(6). 1221–1221. 1 indexed citations
16.
Brodsky, Sergey V., et al.. (2021). A Case of IgA Nephropathy in the Setting of Sezary Syndrome and Mogamulizumab. Journal of the American Society of Nephrology. 32(10S). 580–580.
17.
Reneau, John & Ryan A. Wilcox. (2021). Novel therapies targeting cutaneous T cell lymphomas and their microenvironment. Seminars in Hematology. 58(2). 103–113. 4 indexed citations
18.
Smith, Lauren B., et al.. (2020). Spontaneous Regression of High-Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements: Case Report and Literature Review. Clinical Lymphoma Myeloma & Leukemia. 21(2). e120–e125. 2 indexed citations
19.
Reneau, John & Mrinal M. Patnaik. (2016). 47-Year-Old Man With Pruritus. Mayo Clinic Proceedings. 91(2). 241–245. 1 indexed citations
20.
Lee, Ryang Hwa, Ji Min Yu, Andrea M. Foskett, et al.. (2014). TSG-6 as a biomarker to predict efficacy of human mesenchymal stem/progenitor cells (hMSCs) in modulating sterile inflammation in vivo. Proceedings of the National Academy of Sciences. 111(47). 16766–16771. 154 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Valerie Eaton Breakdown of academic impact, for papers by Yukina Morimoto Breakdown of academic impact, for papers by Wen Bai Breakdown of academic impact, for papers by Nakia D. Spencer Breakdown of academic impact, for papers by Xinran Yuan Breakdown of academic impact, for papers by Kevin Anton Breakdown of academic impact, for papers by Mihai Bogdan Preda Breakdown of academic impact, for papers by Simon Schliffke Breakdown of academic impact, for papers by Rosalba Camicia Breakdown of academic impact, for papers by Cristiana Lavazza
Rankless by CCL
2026